

Press Release

Dayton, Ohio; March 7, 2017 – NovoSource, Inc. will be liquidating all of its corporate assets through a court-ordered auction in late spring (date to be determined). The primary products of NovoSource include the NovoKnee Total Knee System and the NovoHip Total Hip System.

NovoKnee femoral components are offered in a Posterior Stabilized option, as well as a Cruciate Retaining design. The Posterior Stabilized, Cruciate Retaining, and Ultra Congruent highly cross linked polyethylene knee inserts are available in 9mm to 18mm in 2mm increments. The symmetric titanium tibial bases come in six sizes utilizing a cross keel that can be prepared with one simple step. The patella components are offered in four different diameters.

The NovoHip utilizes a titanium plasma spray cementless tapered stem in both a standard and lateralized offset, with 21 different size variations. The titanium acetabular shell is offered in multiple shell configurations, along with vitamin E crosslinked polyethylene. The hip offers both cobalt chrome and BioloX Delta ceramic heads in 28mm, 32mm, 36mm, and 40mm diameters.

The instrument trays for the knee and hip were built with efficiency in mind.

The assets include all intellectual property, inventory, tooling, design history files and 510(k) clearances, trademarks and copyrights, ERP system and servers, and warehouse equipment and furniture. The inventory value of knee and hip implants and instruments are in excess of \$3 million at cost.

There have been over 560 NovoKnees successfully implanted from 2013 to 2014.

If you would like to receive further information regarding the sale, please contact:
Aaron C. Firstenberger, Attorney for Myron N. Terlecky, Receiver at acf@columbuslawyer.net.

Source: NovoSource, Inc., Myron N. Terlecky, Receiver